IL-17 in Chronic Inflammation: From Discovery to Targeting

Miossec, 2009, Interleukin-17 and type 17 helper T cells, N. Engl. J. Med., 361, 888, 10.1056/NEJMra0707449 Cypowyj, 2012, Immunity to infection in IL-17-deficient mice and humans, Eur. J. Immunol., 42, 2246, 10.1002/eji.201242605 Miossec, 2012, Targeting IL-17 and Th17 cells in chronic inflammation, Nat. Rev. Drug Discov., 11, 763, 10.1038/nrd3794 Rouvier, 1993, CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene, J. Immunol., 150, 5445, 10.4049/jimmunol.150.12.5445 Fossiez, 1996, T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines, J. Exp. Med., 183, 2593, 10.1084/jem.183.6.2593 Onishi, 2010, Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease, Immunology, 129, 311, 10.1111/j.1365-2567.2009.03240.x Reynolds, 2010, IL-17 family member cytokines: regulation, and function in innate immunity, Cytokine Growth Factor Rev., 21, 413, 10.1016/j.cytogfr.2010.10.002 Gaffen, 2009, Structure and signalling in the IL-17 receptor family, Nat. Rev. Immunol., 9, 556, 10.1038/nri2586 Kleinschek, 2007, IL-25 regulates Th17 function in autoimmune inflammation, J. Exp. Med., 204, 161, 10.1084/jem.20061738 Yao, 1995, Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor, Immunity, 3, 811, 10.1016/1074-7613(95)90070-5 Gaffen, 2011, Recent advances in the IL-17 cytokine family, Curr. Opin. Immunol., 23, 613, 10.1016/j.coi.2011.07.006 Liu, 2013, Crystal structures of interleukin 17A and its complex with IL-17 receptor A, Nat. Commun., 4, 1888, 10.1038/ncomms2880 Gaffen, 2014, The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing, Nat. Rev. Immunol., 14, 585, 10.1038/nri3707 Zrioual, 2008, IL-17RA and IL-17RC receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood, J. Immunol., 180, 655, 10.4049/jimmunol.180.1.655 Aarvak, 1999, IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells, J. Immunol., 162, 1246, 10.4049/jimmunol.162.3.1246 Yao, 1995, Human IL-17: a novel cytokine derived from T cells, J. Immunol., 155, 5483, 10.4049/jimmunol.155.12.5483 Infante-Duarte, 2000, Microbial lipopeptides induce the production of IL-17 in Th cells, J. Immunol., 165, 6107, 10.4049/jimmunol.165.11.6107 Bettelli, 2007, Th17: the third member of the effector T cell trilogy, Curr. Opin. Immunol., 19, 652, 10.1016/j.coi.2007.07.020 Cua, 2003, Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain, Nature, 421, 744, 10.1038/nature01355 Korn, 2009, IL-17 and Th17 Cells, Annu. Rev. Immunol., 27, 485, 10.1146/annurev.immunol.021908.132710 Noack, 2014, Th17 and regulatory T cell balance in autoimmune and inflammatory diseases, Autoimmun. Rev., 13, 668, 10.1016/j.autrev.2013.12.004 Bettelli, 2006, Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells, Nature, 441, 235, 10.1038/nature04753 Cua, 2010, Innate IL-17-producing cells: the sentinels of the immune system, Nat. Rev. Immunol., 10, 479, 10.1038/nri2800 Kenna, 2012, Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis, Arthritis Rheum., 64, 1420, 10.1002/art.33507 Noordenbos, 2012, Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis, Arthritis Rheum., 64, 99, 10.1002/art.33396 Chabaud, 2001, Enhancing effect of IL-1, IL-17, and TNF-α on macrophage inflammatory protein-3α production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines, J. Immunol., 167, 6015, 10.4049/jimmunol.167.10.6015 Ye, 2001, Interleukin-17 and lung host defense against Klebsiella pneumoniae infection, Am. J. Respir. Cell Mol. Biol., 25, 335, 10.1165/ajrcmb.25.3.4424 Ishigame, 2009, Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses, Immunity, 30, 108, 10.1016/j.immuni.2008.11.009 Cho, 2010, IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice, J. Clin. Invest., 120, 1762, 10.1172/JCI40891 Conti, 2009, Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis, J. Exp. Med., 206, 299, 10.1084/jem.20081463 Kagami, 2010, IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans, J. Immunol., 185, 5453, 10.4049/jimmunol.1001153 de Beaucoudrey, 2008, Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells, J. Exp. Med., 205, 1543, 10.1084/jem.20080321 Puel, 2011, Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity, Science, 332, 65, 10.1126/science.1200439 Okada, 2015, Immunodeficiencies. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations, Science, 349, 606, 10.1126/science.aaa4282 Chabaud, 1999, Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium, Arthritis Rheum., 42, 963, 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E Shahrara, 2010, IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction, J. Immunol., 184, 4479, 10.4049/jimmunol.0901942 Chabaud, 1998, Enhancing effect of IL-17 on IL-1-induced IL-6 and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines, J. Immunol., 161, 409, 10.4049/jimmunol.161.1.409 Toh, 2010, Role of interleukin 17 in arthritis chronicity through survival of synoviocytes via regulation of synoviolin expression, PLoS ONE, 5, e13416, 10.1371/journal.pone.0013416 Koenders, 2005, Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis, Arthritis Rheum., 52, 3239, 10.1002/art.21342 Chabaud, 2001, The combination of tumor necrosis factor alpha blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model, Arthritis Rheum., 44, 1293, 10.1002/1529-0131(200106)44:6<1293::AID-ART221>3.0.CO;2-T Zrioual, 2009, Genome-wide comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis synoviocytes, J. Immunol., 182, 3112, 10.4049/jimmunol.0801967 Hartupee, 2007, IL-17 enhances chemokine gene expression through mRNA stabilization, J. Immunol., 179, 4135, 10.4049/jimmunol.179.6.4135 Fischer, 2015, Combined inhibition of tumor necrosis factor α and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody, Arthritis Rheumatol., 67, 51, 10.1002/art.38896 Miossec, 2012, Targeting IL-17 and TH17 cells in chronic inflammation, Nat. Rev. Drug Discov., 11, 763, 10.1038/nrd3794 Johansen, 2009, Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin, Br. J. Dermatol., 160, 319, 10.1111/j.1365-2133.2008.08902.x Menon, 2014, Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression, Arthritis Rheumatol., 66, 1272, 10.1002/art.38376 Raychaudhuri, 2012, IL-17 receptor and its functional significance in psoriatic arthritis, Mol. Cell. Biochem., 359, 419, 10.1007/s11010-011-1036-6 Metawi, 2011, Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA, Clin. Rheumatol., 30, 1201, 10.1007/s10067-011-1737-y Lubberts, 2004, Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion, Arthritis Rheum., 50, 650, 10.1002/art.20001 Mei, 2011, Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis, Clin. Rheumatol., 30, 269, 10.1007/s10067-010-1647-4 Jandus, 2008, Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides, Arthritis Rheum., 58, 2307, 10.1002/art.23655 Appel, 2011, Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response, Arthritis Res. Ther., 13, R95, 10.1186/ar3370 Ciccia, 2015, Type 3 innate lymphoid cells producing IL-17 and IL-22 are expanded in the gut, in the peripheral blood, synovial fluid and bone marrow of patients with ankylosing spondylitis, Ann. Rheum. Dis., 74, 1739, 10.1136/annrheumdis-2014-206323 Durelli, 2009, T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-β, Ann. Neurol., 65, 499, 10.1002/ana.21652 Tzartos, 2008, Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis, Am. J. Pathol., 172, 146, 10.2353/ajpath.2008.070690 Yen, 2006, IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6, J. Clin. Invest., 116, 1310, 10.1172/JCI21404 Awasthi, 2009, IL-17A directly inhibits Th1 cells and thereby suppresses development of intestinal inflammation, Nat. Immunol., 10, 568, 10.1038/ni0609-568 Jiang, 2014, Elevated levels of Th17 cells and Th17-related cytokines are associated with disease activity in patients with inflammatory bowel disease, Inflamm. Res., 63, 943, 10.1007/s00011-014-0768-7 Sahin, 2014, Serum interleukin 17 levels in patients with Crohn's disease: real life data, Dis. Markers, 2014, 690853, 10.1155/2014/690853 Ueno, 2013, Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients, Inflamm. Bowel Dis., 19, 2522, 10.1097/MIB.0b013e3182a85709 Bartlett, 2015, Targeting the IL-17-Th17 pathway, Nat. Rev. Drug Discov., 14, 11, 10.1038/nrd4518 Hsieh, 2014, FRI0303 discovery and characterization of Abt-122, an anti-TNF/IL-17 DVD-Ig molecule as a potential therapeutic candidate for rheumatoid arthritis, Ann. Rheum. Dis., 73, 495, 10.1136/annrheumdis-2014-eular.4676 Ahmed, 2015, FRI0156 pharmacokinetics of ABT-122, a dual TNF- and IL-17A-targeted DVD-IG™, after single dosing in healthy volunteers and multiple dosing in subjects with rheumatoid arthritis, Ann. Rheum. Dis., 74, 479, 10.1136/annrheumdis-2015-eular.4042 Silacci, 2015, Discovery and characterization of COVA322, a clinical-stage bispecific TNF/IL-17A inhibitor for the treatment of inflammatory diseases, MAbs, 8, 141, 10.1080/19420862.2015.1093266 Isono, 2014, Inhibiting RORγt/Th17 axis for autoimmune disorders, Drug Discov. Today, 19, 1205, 10.1016/j.drudis.2014.04.012 Solt, 2011, Suppression of Th17 differentiation and autoimmunity by a synthetic ROR ligand, Nature, 472, 491, 10.1038/nature10075 Xiao, 2014, Small-molecule RORγt antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms, Immunity, 40, 477, 10.1016/j.immuni.2014.04.004 Hueber, 2010, Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis, Sci. Transl. Med., 2, 52ra72, 10.1126/scitranslmed.3001107 Langley, 2014, Secukinumab in plaque psoriasis – results of two Phase 3 trials, N. Engl. J. Med., 371, 326, 10.1056/NEJMoa1314258 Thaci, 2015, Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial, J. Am. Acad. Dermatol., 73, 400, 10.1016/j.jaad.2015.05.013 Leonardi, 2012, Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis, N. Engl. J. Med., 366, 1190, 10.1056/NEJMoa1109997 Griffiths, 2015, Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two Phase 3 randomised trials, Lancet, 386, 541, 10.1016/S0140-6736(15)60125-8 Papp, 2012, Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis, N. Engl. J. Med., 366, 1181, 10.1056/NEJMoa1109017 Papp, 2014, Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment, J. Am. Acad. Dermatol., 71, 1183, 10.1016/j.jaad.2014.08.039 Lebwohl, 2015, Phase 3 studies comparing brodalumab with ustekinumab in psoriasis, N. Engl. J. Med., 373, 1318, 10.1056/NEJMoa1503824 Sofen, 2014, Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis, J. Allergy Clin. Immunol., 133, 1032, 10.1016/j.jaci.2014.01.025 Gordon, 2015, A Phase 2 trial of guselkumab versus adalimumab for plaque psoriasis, N. Engl. J. Med., 373, 136, 10.1056/NEJMoa1501646 Kopp, 2015, Clinical improvement in psoriasis with specific targeting of interleukin-23, Nature, 521, 222, 10.1038/nature14175 Papp, 2015, Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a Phase IIb randomized placebo-controlled trial, Br. J. Dermatol., 173, 930, 10.1111/bjd.13932 McInnes, 2014, Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, Phase II proof-of-concept trial, Ann. Rheum. Dis., 73, 349, 10.1136/annrheumdis-2012-202646 McInnes, 2015, Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet, 386, 1137, 10.1016/S0140-6736(15)61134-5 Mease, 2015, Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis, N. Engl. J. Med., 373, 1329, 10.1056/NEJMoa1412679 Mease, 2014, Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis, N. Engl. J. Med., 370, 2295, 10.1056/NEJMoa1315231 Baeten, 2013, Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial, Lancet, 382, 1705, 10.1016/S0140-6736(13)61134-4 Baraliakos, 2015, Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study, Ann. Rheum. Dis. Genovese, 2013, Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a Phase II, dose-finding, double-blind, randomised, placebo controlled study, Ann. Rheum. Dis., 72, 863, 10.1136/annrheumdis-2012-201601 Genovese, 2014, One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: Phase II, dose-finding, double-blind, randomized, placebo-controlled study, J. Rheumatol., 41, 414, 10.3899/jrheum.130637 Strand, 2014, Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds, Health Qual. Life Outcomes, 12, 31, 10.1186/1477-7525-12-31 Burmester, 2015, Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis, Rheumatology (Oxford), 55, 49, 10.1093/rheumatology/kev258 Genovese, 2010, LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled, proof-of-concept study, Arthritis Rheum., 62, 929, 10.1002/art.27334 Genovese, 2014, A Phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors, Arthritis Rheum., 66, 1693, 10.1002/art.38617 Pavelka, 2015, A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to methotrexate, J. Rheumatol., 42, 912, 10.3899/jrheum.141271 Martin, 2013, A Phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis, Arthritis Res. Ther., 15, R164, 10.1186/ar4347 van Oosten, 1996, Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2, Neurology, 47, 1531, 10.1212/WNL.47.6.1531 Mardiguian, 2013, Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE ABH mice, Am. J. Pathol., 182, 2071, 10.1016/j.ajpath.2013.02.029 Knier, 2014, Novel monoclonal antibodies for therapy of multiple sclerosis, Expert Opin. Biol. Ther., 14, 503, 10.1517/14712598.2014.887676 Luchtman, 2014, IL-17 and related cytokines involved in the pathology and immunotherapy of multiple sclerosis: current and future developments, Cytokine Growth Factor Rev., 25, 403, 10.1016/j.cytogfr.2014.07.013 Hueber, 2012, Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial, Gut, 61, 1693, 10.1136/gutjnl-2011-301668 Patel, 2013, Effect of IL-17A blockade with secukinumab in autoimmune diseases, Ann. Rheum. Dis., 72, ii116, 10.1136/annrheumdis-2012-202371 Raine, 2012, Seventeen in Crohn's disease: less prime than we thought?, Gut, 61, 1653, 10.1136/gutjnl-2012-302525 Maxwell, 2015, Differential roles for interleukin-23 and interleukin-17 in intestinal immunoregulation, Immunity, 43, 739, 10.1016/j.immuni.2015.08.019 Busse, 2013, Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma, Am. J. Respir. Crit. Care Med., 188, 1294, 10.1164/rccm.201212-2318OC Grosskreutz, 2015, Dry eye signs and symptoms persist during systemic neutralization of IL-1β by canakinumab or IL-17A by secukinumab, Cornea, 34, 1551, 10.1097/ICO.0000000000000627 Danesh, 2016, Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States, J. Am. Acad. Dermatol., 74, 190, 10.1016/j.jaad.2015.08.057 Ndongo-Thiam, 2015, A cell-based bioassay for circulating bioactive IL-17: application to destruction in rheumatoid arthritis, Ann. Rheum. Dis., 74, 1629, 10.1136/annrheumdis-2014-207110